Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is set to announce second quarter earning results on Tuesday 11th August 2020, after market close.
Previous Quarter Performance
Aurinia Pharmaceuticals Inc disclosed loss for the first quarter of $ 0.15 per share, from the revenue of $ 0.03 million. The quarterly earnings down 50.00 percent compared with the same quarter last year. Street analysts expected Aurinia Pharmaceuticals Inc to report loss of $ 0.15 per share on revenue of $ 0.05 million for the first quarter. The bottom line results street analysts by $ 0 or , at the same time, top line results fell short of analysts by $ 0.02 million or 40 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Aurinia Pharmaceuticals Inc
Stock Performance
According to the previous trading day, closing price of AUPH was $ 14.36, representing a 307.95 % increase from the 52 week low of $ 3.52 and a 34.52 % decrease over the 52 week high of $ 21.93.
The company has a market capital of $ 1.82 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”AUPH” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Aurinia Pharmaceuticals Inc will be hosting a conference call at 4:30 PM eastern time on 11th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.auriniapharma.com
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc.
